Entrada Therapeutics (NASDAQ:TRDA) Trading 1.1% Higher - Still a Buy?

Key Points

• Entrada Therapeutics shares rose 1.1% to $7.40 amid heavier-than-usual trading volume, with about 603,000 shares changing hands versus a 308,000-share average.
• Analyst sentiment is mixed but leans cautious: Oppenheimer raised its target to $23 and kept an outperform rating, while others cut targets or downgraded the stock. Overall, the stock carries an average Hold rating and a consensus target price of $17.50.
• The company remains unprofitable, but its latest quarter beat EPS estimates with a loss of $0.95 per share; however, revenue of $0.88 million fell well short of expectations. Insider activity was mixed, with one director buying shares while the COO sold shares under a pre-arranged trading plan.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) shares traded up 1.1% during mid-day trading on Thursday . The stock traded as high as $7.49 and last traded at $7.40. Approximately 603,163 shares traded hands during trading, an increase of 96% from the average session volume of 308,410 shares. The stock had previously closed at $7.32.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several recent research reports. Oppenheimer boosted their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an "outperform" rating in a research note on Monday, April 6th. Wall Street Zen downgraded shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Guggenheim decreased their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a report on Monday, June 8th. Cantor Fitzgerald assumed coverage on shares of Entrada Therapeutics in a research report on Wednesday, April 1st. They set an "overweight" rating for the company. Finally, Weiss Ratings lowered shares of Entrada Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Thursday, June 11th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Entrada Therapeutics presently has an average rating of "Hold" and an average target price of $17.50.

Entrada Therapeutics Stock Performance

The firm has a market cap of $287.28 million, a price-to-earnings ratio of -1.85 and a beta of -0.26. The stock's fifty day moving average is $7.48 and its two-hundred day moving average is $10.27.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. Sell-side analysts predict that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, Director Bernhardt G. Zeiher bought 5,000 shares of the business's stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $5.86 per share, with a total value of $29,300.00. Following the purchase, the director directly owned 5,000 shares of the company's stock, valued at approximately $29,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Nathan J. Dowden sold 15,000 shares of the business's stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.33, for a total value of $229,950.00. Following the transaction, the chief operating officer owned 198,588 shares of the company's stock, valued at $3,044,354.04. This trade represents a 7.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.49% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company's stock worth $4,245,000 after purchasing an additional 42,479 shares during the period. Rhumbline Advisers grew its position in Entrada Therapeutics by 8.3% in the 2nd quarter. Rhumbline Advisers now owns 39,095 shares of the company's stock valued at $263,000 after buying an additional 2,982 shares in the last quarter. American Century Companies Inc. increased its stake in Entrada Therapeutics by 10.8% during the 2nd quarter. American Century Companies Inc. now owns 75,094 shares of the company's stock valued at $505,000 after buying an additional 7,301 shares during the period. Prudential Financial Inc. increased its stake in Entrada Therapeutics by 23.4% during the 2nd quarter. Prudential Financial Inc. now owns 28,340 shares of the company's stock valued at $190,000 after buying an additional 5,370 shares during the period. Finally, Invesco Ltd. raised its position in shares of Entrada Therapeutics by 34.2% during the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company's stock worth $150,000 after buying an additional 5,702 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.